Non-structural protein 14 (nsp14) (nsp14)

Non-structural protein 14 (nsp14) is a multifunctional enzyme essential for the replication and pathogenesis of SARS-CoV-2 (UniProt P0DTD1). It possesses two distinct catalytic activities: an N-terminal 3-to-5 exoribonuclease (ExoN) domain and a C-terminal N7-methyltransferase (MTase) domain (Ogando et al., 2020). The ExoN domain provides a critical proofreading function by excising misincorporated nucleotides and nucleoside analogs from the nascent RNA strand, which ensures high-fidelity replication of the large viral genome and contributes to resistance against antiviral drugs like remdesivir and ribavirin (Gribble et al., 2021). The MTase domain catalyzes the N7-guanine methylation of the viral RNA cap, a process necessary for efficient viral protein translation and for shielding viral RNA from host innate immune sensors (Saramago et al., 2021). Additionally, nsp14 has been shown to modulate host cell pathways, such as the activation of NF-κB, which triggers the production of pro-inflammatory cytokines like IL-6 and IL-8, potentially leading to severe COVID-19 complications (Zaffagni et al., 2021). Because of its indispensable roles in viral survival and immune evasion, nsp14 is considered a highly promising target for the development of novel, broad-spectrum antiviral therapeutics, with experimental inhibitors like C10 showing potent activity in preclinical models (Nature Communications, 2025).

Other names

SARS-CoV-2 ExoribonucleaseExoNN7-MTaseNon-structural protein 14Guanine-N7-methyltransferaseSARS-CoV-2 nsp14

Inhibition of the 3-to-5 exoribonuclease activity prevents viral proofreading, leading to lethal mutagenesis or increased sensitivity to nucleoside analogs, while inhibition of the N7-methyltransferase activity impairs viral mRNA capping, translation, and immune evasion.